Finerenone in patients with severe heart failure: The FINEARTS-HF trial.

ABSTRACT:

Aims

While patients with severe heart failure (HF) were historically considered to have reduced left ventricular ejection fraction (LVEF), it is increasingly recognized that severe HF occurs across the full spectrum of LVEF. The aim of this study was to assess prevalence, cardiovascular (CV) outcome risk, and treatment response to the non-steroidal mineralocorticoid receptor antagonist finerenone among patients with severe HF in FINEARTS-HF.

Methods and results

Treatment effects of finerenone on the primary endpoint of total (first and recurrent) HF events and CV death were assessed by severe HF status, as defined by the adapted multiparametric ESC-HFA criteria including New York heart Association functional class III/IV, hospitalization for HF within the previous 12 months,

SUBMITTER: Inciardi RM 

PROVIDER: S-EPMC12803546 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature